Recent 8-K filings for ACXP

• October 16, 2026, 4:30 PM ET other materiality 0.15 neutral item 5.07

  Acurx holders re-elect Luci, Dean as Class II directors; ratify CohnReznick for FY2026

  Annual meeting held Oct 16, 2026; record date Aug 20, 2026 with 5,471,297 shares outstanding; quorum of 2,890,899 shares, or 52.83%.

• April 16, 2026, 7:59 PM ET other material materiality 0.65 neutral item 1.01item 3.02item 8.01item 9.01 ◈ Material Agreements

  Acurx raises ~$2.5M in registered direct offering plus up to $4.6M from warrants

  Priced 825,085 shares (or pre-funded warrants) at $3.03/share for ~$2.5M gross proceeds.

• March 9, 2026, 7:59 PM ET other material materiality 0.75 positive item 5.02item 8.01item 9.01

  Acurx launches ibezapolstat pilot trial in recurrent CDI; Phase 2 showed 96% cure, no recurrence

  CEO, Executive Chairman, CFO take 10% base salary cut; director cash retainers also reduced 10%, effective April 1, 2026.

• September 22, 2025, 7:59 PM ET other materiality 0.35 neutral item 5.03item 9.01 ◈ Governance Changes

  Acurx increases authorized common stock from 200 million to 250 million shares

  Stockholders approved amendment at special meeting on September 16, 2025.

• September 19, 2025, 7:59 PM ET other material materiality 0.15 neutral item 5.07

  Acurx shareholders approve warrant exercise and authorized share increase at special meeting

  Proposal 1 (warrant exercise for Nasdaq compliance): 8,816,581 for, 602,155 against, 9,823,429 broker non-votes.

• July 31, 2025, 7:59 PM ET other material materiality 0.55 neutral item 3.03item 5.03item 8.01item 9.01 ◈ Governance Changes

  Acurx Pharmaceuticals announces 1-for-20 reverse stock split effective August 4, 2025 to regain Nasdaq compliance

  Reverse split ratio 1-for-20; effective 4:01 p.m. ET on August 4, 2025.

• July 17, 2025, 7:59 PM ET other material materiality 0.70 neutral item 5.07

  Acurx shareholders approve reverse split, equity plan increase, and director elections at annual meeting

  All six proposals passed at July 17 meeting; 74.38% of shares represented.

• June 20, 2025, 7:59 PM ET other material materiality 0.70 neutral item 1.01item 3.02item 8.01item 9.01

  Acurx Pharma raises $2.67M via warrant exercise; issues new warrants for ~8.89M shares

  Entered warrant inducement agreement; holder exercised ~4.45M existing warrants at reduced $0.60/share, gross proceeds $2.67M.

• May 13, 2025, 7:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01

  Acurx Q1 net loss narrows to $2.1M ($0.11/sh); cash $4.6M; EMA guidance for ibezapolstat Phase 3

  Net loss $2.1M ($0.11 diluted EPS) vs $4.4M ($0.28) Q1 2024; R&D fell to $0.6M, G&A to $1.6M.

• May 8, 2025, 7:59 PM ET other material materiality 0.75 neutral item 1.01item 3.02item 9.01

  Acurx Pharmaceuticals secures up to $12M equity line from Lincoln Park Capital

  Lincoln Park committed to purchase up to $12M in common stock over 24 months.

• March 28, 2025, 7:59 PM ET regulatory materiality 0.85 negative item 3.01 ◈ Listing & Compliance Notices

  Acurx Pharma receives Nasdaq notice for non-compliance with equity requirement

  Notice based on 10-K for FY 2024; stockholders' equity fell below $2.5M minimum.

• March 18, 2025, 7:59 PM ET earnings materiality 0.65 positive item 2.02item 9.01

  Acurx Pharma reports FY 2024 net loss $14.1M; cash $3.7M; EMA guidance for Phase 3

  Net loss Q4 2024 $2.8M ($0.16/diluted share) vs $5.1M ($0.37) in Q4 2023; FY 2024 net loss $14.1M ($0.87) vs $14.6M ($1.15).

• March 10, 2025, 7:59 PM ET other material materiality 0.55 neutral item 1.01item 3.02item 8.01item 9.01

  Acurx Pharmaceuticals raises $1.1M in registered direct offering and private warrants

  Aggregate gross proceeds of ~$1.1M from 2.15M common shares and 595K pre-funded warrants at $0.40/share.

• February 26, 2025, 6:59 PM ET regulatory materiality 0.60 negative item 3.01 ◈ Listing & Compliance Notices

  Acurx Pharmaceuticals receives Nasdaq minimum bid price deficiency notice; 180-day cure period

  Stock closed below $1.00 for 31 consecutive business days, triggering Nasdaq Listing Rule 5550(a)(2) deficiency.

• January 7, 2025, 6:59 PM ET other material materiality 0.65 neutral item 1.01item 3.02item 8.01item 9.01

  Acurx Pharmaceuticals prices $2.5M registered direct offering of 2.46M shares at $1.015

  Gross proceeds ~$2.5M from 2,463,058 shares at $1.015/share in registered direct offering.

• November 13, 2024, 6:59 PM ET earnings materiality 0.50 neutral item 2.02item 9.01

  Acurx Pharma Q3 net loss $2.8M; cash $5.8M; advancing ibezapolstat Phase 3

  Net loss $2.8M ($0.17/diluted share) vs $3.1M ($0.24) in Q3 2023; nine-month net loss $11.3M.

• August 9, 2024, 7:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01

  Acurx Q2 net loss $4.1M, cash $6.4M; FDA confirms Phase 3 readiness for ibezapolstat

  Net loss of $4.1M ($0.26/diluted share) for Q2 2024 vs. $3.4M ($0.28) in Q2 2023.

• June 17, 2024, 7:59 PM ET other material materiality 0.15 neutral item 5.07

  Acurx Pharmaceuticals announces results of annual shareholder meeting; directors elected, auditor ratified

  Quorum of 67.29% of outstanding shares (10,648,350 of 15,823,102) was present at June 17, 2024 Annual Meeting.

• May 15, 2024, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01 ◈ Earnings Releases

  Acurx Pharma Q1 net loss $4.4M; Phase 2b data positive, FDA agrees on Phase 3 plan

  Net loss of $4.4M ($0.28/diluted share) vs $2.9M loss in Q1 2023; R&D expenses $1.6M, G&A $2.8M.

• March 18, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01 ◈ Earnings Releases ×2

  Acurx reports Q4 net loss $5.1M; ibezapolstat Phase 2b shows 96% cure rate

  Q4 net loss $5.1M ($0.37/shr); full year net loss $14.6M ($1.15/shr).

• November 15, 2023, 6:59 PM ET other material materiality 0.50 neutral item 1.01item 9.01 ◈ Material Agreements

  Acurx Pharmaceuticals enters $17M ATM equity offering with A.G.P.

  Up to $17M of common stock may be sold from time to time in at-the-market offerings.

• November 14, 2023, 6:59 PM ET earnings materiality 0.70 positive item 2.02item 9.01 ◈ Earnings Releases

  Acurx reports Q3 net loss of $3.1M; ibezapolstat Phase 2 shows 96% cure rate, advancing to Phase 3

  Net loss $3.1M ($0.24/diluted share) vs $3.5M ($0.32) in Q3 2022; cash $7.1M at Sept 30, 2023.

• November 3, 2023, 7:59 PM ET other material materiality 0.85 positive item 8.01item 9.01

  Acurx reports 96% clinical cure rate in Phase 2 trial of ibezapolstat for C. difficile infection

  96% clinical cure rate (25/26 patients) in combined Phase 2a and 2b trials of ibezapolstat.

• October 2, 2023, 7:59 PM ET other material materiality 0.75 positive item 8.01item 9.01

  Acurx discontinues Phase 2b ibezapolstat trial early on high cure rates, no safety concerns; Phase 3 accelerated

  Phase 2b discontinued after blinded data showed high clinical cure rates for ibezapolstat and vancomycin, with no emerging safety concerns.

• August 14, 2023, 7:59 PM ET earnings materiality 0.55 negative item 2.02item 9.01 ◈ Earnings Releases

  Acurx Pharma Q2 net loss widens to $3.4M; Phase 2b enrollment ongoing

  Net loss Q2 2023: $3.4M ($0.28/sh) vs $2.6M ($0.26/sh) in Q2 2022.

• June 20, 2023, 7:59 PM ET other materiality 0.25 neutral item 5.03item 5.07item 9.01 ◈ Shareholder Votes ×3◈ Governance Changes

  Acurx Pharmaceuticals stockholders approve officer exculpation amendment and reelect directors at annual meeting

  Stockholders elected David P. Luci and Jack H. Dean as Class II directors with 5,749,190 and 5,575,112 votes for, respectively.

• May 17, 2023, 7:59 PM ET other material materiality 0.70 neutral item 1.01item 3.02item 3.03item 9.01 ◈ Material Agreements ×3

  Acurx Pharma prices $4M registered direct offering of common stock and warrants

  Gross proceeds of ~$4M from sale of 1,333,333 shares (or pre-funded warrants) at $3.00 per share.

• March 16, 2023, 7:59 PM ET earnings materiality 0.60 neutral item 2.02item 8.01item 9.01

  Acurx reports Q4/FY2022 net loss; Phase 2b CDI trial interim IDMC review at 36 patients

  Cash $9.1M at Dec 31, 2022 vs $13.0M a year earlier.

• November 14, 2022, 6:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01 ◈ Earnings Releases ×2

  Acurx reports Q3 net loss of $3.5M; cash $10.6M; Phase 2b enrollment continues

  Net loss of $3.5M ($0.32 per diluted share) for Q3 2022, vs $4.6M ($0.46) in Q3 2021.

• August 15, 2022, 7:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01

  Acurx reports Q2 2022 net loss of $2.6M; Phase 2b trial enrollment continues with site expansion

  Net loss $2.6M ($0.26/diluted) for Q2 2022 vs $4.0M ($0.57) a year ago.

• July 25, 2022, 7:59 PM ET other material materiality 0.55 neutral item 1.01item 2.02item 3.02item 5.05item 9.01

  Acurx Pharmaceuticals raises $4.225M in registered direct offering; reports $9.1M cash

  Gross proceeds of ~$4.225M from sale of 1,289,980 shares/pre-funded warrants at $3.25 (institutional) and $3.80 (executives).

• June 7, 2022, 7:59 PM ET other materiality 0.10 neutral item 5.07

  Acurx shareholders elect directors and ratify auditor at 2022 annual meeting

  Carl V. Sailer elected with 3,743,543 votes for, 289,750 withheld; broker non-votes 1,656,180.

• May 11, 2022, 7:59 PM ET earnings materiality 0.55 neutral item 2.02item 9.01

  Acurx Pharma Q1 net loss $2.7M ($0.26/shr); Phase 2b CDI trial progressing

  Cash $11.1M at March 31, 2022, down from $13.0M at Dec 31, 2021.

• March 17, 2022, 7:59 PM ET earnings materiality 0.55 neutral item 2.02item 9.01

  Acurx reports Q4/FY2021 results; Phase 2b enrollment ongoing for ibezapolstat

  R&D expense FY2021: $2.0M (vs $2.2M in 2020); Q4 2021: $0.7M (vs $0.5M).

• November 16, 2021, 6:59 PM ET earnings materiality 0.55 neutral item 2.02item 9.01

  Acurx Pharma Q3 net loss $4.6M; Phase 2b enrollment underway

  Net loss of $4.6M ($0.46/diluted share) for Q3 2021 vs. $1.3M ($0.21) in Q3 2020.

• August 16, 2021, 7:59 PM ET earnings materiality 0.70 negative item 2.02item 9.01

  Acurx Q2 2021 net loss $4.0M ($0.57/diluted share); IPO raised $17.25M gross

  Net loss of $4.0M for Q2 2021 vs $0.9M loss in Q2 2020; R&D expenses down to $0.1M from $0.4M.

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.85 · Median 0.60 · Most common event other_material

6 positive 4 negative 26 neutral

source · ACXP on sec.gov